Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort.
Saved in:
| Title: | Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort. |
|---|---|
| Authors: | McFaline-Figueroa JR; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Brain & Spine Tumor Center, Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Sun L; Department of Neurosurgery, University of California Los Angeles, Los Angeles, CA, USA., Youssef GC; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Huang R; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Li G; Department of Biostatistics, Jonathan and Karin Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA., Kim J; Department of Biostatistics, Jonathan and Karin Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA., Lee EQ; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Nayak L; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Chukwueke U; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Beroukhim R; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Batchelor TT; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Chiocca EA; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Everson RG; Department of Neurosurgery, University of California Los Angeles, Los Angeles, CA, USA.; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA., Doherty L; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Stefanik J; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Partridge K; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Spearman A; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Myers A; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Westergaard C; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Russ A; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lavallee M; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Smokovich A; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., LaForest-Roys C; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Garcia Fox R; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., McCluskey C; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bi WL; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Arnaout O; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Peruzzi P; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Cosgrove GR; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Ligon KL; Division of Neuropathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Arrillaga-Romany I; Division of Neuro-Oncology, Mass General Cancer Center, Harvard Medical School, Boston, MA, USA., Clarke JL; Departments of Neurology and Neurological Surgery, University of California San Francisco, San Francisco, CA, USA., Reardon DA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cloughesy TF; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Prins RM; Department of Neurosurgery, University of California Los Angeles, Los Angeles, CA, USA.; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Patrick_Wen@dfci.harvard.edu.; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Patrick_Wen@dfci.harvard.edu. |
| Source: | Nature communications [Nat Commun] 2024 Dec 30; Vol. 15 (1), pp. 10757. Date of Electronic Publication: 2024 Dec 30. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
